Taysha raises $215M, refinances loan and advances TSHA‑102 Rett; heavy R&D burn persists

Taysha Gene Therapies, Inc. (TSHA on NASDAQ)

Quick summary - what's happening inside
Taysha raised a large equity tranche in May 2025 and entered a refinanced term‑loan in August 2025, materially improving near‑term liquidity while continuing to spend heavily on its lead gene‑therapy program TSHA‑102 (Rett syndrome). Clinical Part A data look promising and regulatory engagement (FDA, Health Canada) has advanced; the company remains unprofitable and dependent on external financing and partner/license dynamics (Astellas option).

Key points & statistics
- Cash and cash equivalents: $312.8 million (June 30, 2025).
- Cash, cash equivalents and restricted cash: $315.361 million (end of period).
- Total assets: $333.331 million (June 30, 2025).
- Total liabilities: $84.604 million (June 30, 2025).
- Term loan (fair value): $41.051 million; Success Fee liability: $1.229 million; SSI/Warrant liability: $0.609 million (all June 30, 2025).
- Stockholders' equity: $248.727 million (June 30, 2025).
- Accumulated deficit: $(650.716) million (June 30, 2025).
- Shares outstanding: 272,794,885 (as of August 12, 2025).
- Weighted average common shares (Q2 2025): 297,988,978.
- Q2 2025 revenue: $1.986 million; 6‑month revenue: $4.288 million (Astellas R&D contract related).
- Q2 2025 R&D expense: $20.141 million; 6‑month R&D: $35.706 million.
- Q2 2025 G&A expense: $8.598 million; 6‑month G&A: $16.756 million.
- Q2 2025 net loss: $(26.882) million; 6‑month net loss: $(48.411) million.
- Net cash from financing (six months): $216.236 million (May 2025 offering net proceeds ≈ $215.6M).

Income statement - positives
- Revenue recognition from the Astellas agreement provides non‑dilutive program funding and reflects active R&D collaboration (Rett research services recognized: $4.3M YTD).
- Stock‑based compensation is disclosed and modest relative to total burn (stock comp ~ $6.48M YTD split between R&D and G&A).
- Interest income increased (Q2 interest/dividends ~$1.86M) thanks to cash balances - helps offset some operating burn.
- Management tightened financing runway: May 2025 equity raise (~$215.6M net) plus August 7, 2025 New Trinity Term Loan ($50M drawn) materially extends runway (company states cash sufficient for at least 12 months; management believes runway into 2028).

Income statement - negatives / risks
- Heavy operating loss and cash burn: Q2 operating expenses $28.739M, primarily R&D; six‑month operating cash use ~ $42.2M.
- Accumulated deficit is large at $(650.7)M - company remains unprofitable with no product revenue.
- Revenue is small and tied to collaboration accounting (Astellas); not product sales - limited diversification of revenue sources.
- Fair‑value accounting volatility: changes in fair value of Trinity term loan and warrant liabilities create non‑cash earnings volatility (e.g., change in fair value of term loan expense $2.991M YTD).
- Dependence on future financings and milestones - despite recent raises and new loan, further funding may be required to complete pivotal trials and potential commercialization.
- Legal and regulatory overhang: consolidated derivative litigation, SEC subpoenas (production completed April 2025) - outcomes uncertain and could be costly or distracting.

Other material items
- Clinical/regulatory: TSHA‑102 (Rett) - Part A data reported favorable (no treatment‑related SAEs/DLTs in 12 patients per August 4, 2025 cutoff); FDA written alignment for pivotal Part B; site activation commenced and enrollment expected Q4 2025.
- Astellas option: Rett Data Package delivered mid‑2025; Astellas has 90 days to decide whether to exercise Rett option - that decision could materially change strategy/value extraction.
- Debt refinance (subsequent event): on August 7, 2025 Taysha replaced prior Trinity loan with New Trinity Term Loan - Tranche A $50M drawn, Tranche B/C contingent on BLA milestones; interest floor reduced (WSJ+4% or 11.5% floor vs prior WSJ+4.5% / 12.75%).
- Commitments: operating lease obligations and manufacturing/clinical purchase commitments remain substantial (~$26.3M operating lease payments total schedule disclosed; ~$19.5M cancellable purchase obligations to CROs/vendors noted).
- Deferred revenue fell from $9.8M (Dec 31, 2024) to $5.485M (June 30, 2025) as R&D services were delivered.

Bottom line
Taysha is a clinical‑stage biotech that dramatically improved near‑term liquidity via a large May 2025 equity raise and an August 2025 term‑loan refinance while advancing TSHA‑102 toward a pivotal trial with supportive early signals and regulatory alignment. That progress reduces some near‑term funding risk but the company still runs at a high R&D burn, posts material operating losses, remains dependent on external financing/partner decisions (Astellas), and faces legal/regulatory uncertainty. Investors should weigh promising clinical momentum and a stronger cash position against ongoing losses, milestone financing needs, and valuation volatility from fair‑value accounting and contingent liabilities.

If you want, I can prepare a 1‑page financial snapshot (PDF/print) or a short chart of burn vs runway using the company's disclosed figures.